35-Year-Old Female | Newly Diagnosed T2DM | HbA1c 12%

Clinical Assessment

• Type 1 DM / LADA - check GAD-65 antibodies, c-peptide, anti-islet antibodies (especially in a young woman with possible rapid-onset)
• Symptomatic hyperglycemia - polyuria, polydipsia, weight loss, ketosis?
• Secondary causes - steroid use, PCOS, Cushing's

ADA 2025 Treatment Algorithm (HbA1c ≥10%)

Step 1 - Assess for Immediate Insulin Need

• Symptomatic hyperglycemia (polyuria, polydipsia, weight loss)
• Random glucose ≥250 mg/dL
• HbA1c ≥10% with ketosis
• Significantly unwell

"Insulin can be used as initial therapy in individuals with severe hyperglycemia (FPG 250-300 mg/dL) or in those who are symptomatic from the hyperglycemia. This approach reduces glucose toxicity to the islet cells, improves endogenous insulin secretion, and possibly allows oral agents to work better subsequently." - Harrison's Principles of Internal Medicine 22e

Step 2 - Combination Oral Therapy (if asymptomatic, no ketosis)

• Metformin + GLP-1 RA (e.g., semaglutide) - best for weight loss + HbA1c reduction
• Metformin + SGLT-2 inhibitor - if CV/renal risk protection needed
• Metformin + Tirzepatide (GIP/GLP-1 dual agonist) - superior HbA1c reduction, maximal weight loss

Per ADA 2025: when HbA1c is ≥1.5% above goal, initiate combination therapy from the outset rather than a stepwise approach. At HbA1c 12%, the patient is 5% above the target of 7%, making early combination mandatory.

Target & Monitoring

• Repeat HbA1c in 3 months (not 6) given severity
• Start CGM (continuous glucose monitoring) if available
• Screen for complications at diagnosis: microalbuminuria, serum creatinine, eGFR, lipid panel, fundus exam, foot exam, ECG

Lifestyle Modifications (Essential)

• Medical Nutrition Therapy (MNT): Low refined carbohydrate diet, caloric deficit to achieve 5-10% weight loss
• Physical activity: 150 min/week moderate aerobic exercise + resistance training 2-3x/week
• Weight loss target: 5-10% body weight - can reduce HbA1c by 1-2% independently
• Smoking cessation, alcohol moderation

Special Considerations in a 35-Year-Old Female

1. Reproductive health: Counsel about contraception - poor glycemic control (HbA1c >7%) is associated with increased risk of congenital anomalies if she becomes pregnant. Metformin is safe in pregnancy; GLP-1 RAs and SGLT-2 inhibitors should be stopped before/during pregnancy.
2. PCOS: Common in young women with T2DM - screen with clinical features. Metformin also treats PCOS; pioglitazone is an option.
3. Thyroid: Check TSH - hypothyroidism can worsen glucose control and is more common in women.
4. Mental health: Screen for diabetes distress and depression (ADA 2025 recommendation at diagnosis and annually).
5. Cardiovascular risk: At 35 with HbA1c 12%, assess ASCVD risk - check lipids, BP, family history. A statin may be warranted.

Proposed Initial Regimen (Practical)

1. Metformin 500 mg with dinner for 1 week → increase to 500 mg BD → titrate to 1000 mg BD (2000 mg/day over 4-6 weeks)
2. Add GLP-1 RA (e.g., oral semaglutide 3 mg OD → 7 mg → 14 mg) OR SGLT-2 inhibitor
3. Consider short-term basal insulin (10 units glargine at bedtime) if glucose remains >250 mg/dL at 4-6 weeks
4. Review at 3 months with repeat HbA1c

1. Start basal insulin (glargine 0.2 U/kg at bedtime, adjust by 2 units every 3 days targeting FBG 80-130)
2. Add metformin once ketosis resolved
3. Once glucose controlled, may be able to step down insulin and rely on oral combination